# Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

> **NCT07168993** · NA · RECRUITING · sponsor: **bioAffinity Technologies Inc.** · enrollment: 2063 (estimated)

## Conditions studied

- Lung Cancer (Diagnosis)

## Interventions

- **OTHER:** Standard medical treatment
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07168993
- **Lead sponsor:** bioAffinity Technologies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-25
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 2063 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168993, "Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07168993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*